On April 29, 2026 Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, reported a business update on its myvac platform, and its individualized neoantigen therapeutic vaccine (INTV) TG4050, and upcoming plans, including its financial position as of March 31, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

TG4050, Transgene’s first INTV from its myvac platform continues to progress according to plan in the adjuvant treatment of head and neck cancer

TG4050 is designed to stimulate a strong and individualized immune response aimed at preventing relapse in HPV-negative head and neck cancer (HNSCC1) patients following surgery and adjuvant (chemo)radiotherapy. It is currently under evaluation in a randomized multicenter Phase 1/2 clinical trial (NCT04183166).

As a monotherapy, TG4050 met all trial endpoints in the Phase 1 part of the trial and induced long-lasting immune responses to individualized vaccine neoantigens that were sustained for up to two years after treatment initiation. All patients treated were disease-free at 2 years, providing robust clinical proof of principle.

A comprehensive analysis of these positive clinical and translational data from the Phase 1 part of the randomized Phase 1/2 trial of TG4050 was published on the preprint platform medRxiv, in January 2026 (see press release). The data suggest that individualized treatment with TG4050 has the potential to prevent cancer relapses. The article is under review by a peer-reviewed journal. These data have also been presented orally at the World Vaccine Congress (WVC) (see press release).

3-year disease-free survival (DFS) follow-up of Phase 1 patients is expected in Q2/Q3 2026.
Transgene announced that the randomization of the Phase 2 part of the Phase 1/2 trial for adjuvant treatment of HNSCC has been completed (see press release).

The primary endpoint of the trial is 2-year DFS. Transgene expects to communicate these top-line results by the end of Q1 2028.
Early April 2026, Transgene and NEC Bio signed a license agreement to advance the clinical development of TG4050 in head and neck cancer (see press release). Transgene secures access to NEC’s AI-based neoantigen prediction platform, as well as rights to enable TG4050’s further clinical development and to support commercialization and potential partnering of the program. Under this agreement, Transgene has paid a technology access fee of €2.5 million in Transgene shares as well as a first tranche of €0.5 million from a total payment of a total €2.5 million in cash that will be paid out in several instalments through early 2028. Additional development and milestone payments will be paid upon progress of the clinical development of TG4050 in head and neck cancer.

Expanding the value of the myvac platform

Transgene’s INTV platform, myvac, has the potential to generate INTVs that could be used to improve treatment across a range of solid tumors where in many cases a significant unmet medical need remains.

In parallel with the ongoing Phase 1/2 trial in HNSCC, Transgene is progressing with start-up activities for a new Phase 1 trial in a second indication in an early treatment setting, with the aim of initiating later in 2026, as soon as all conditions are met.
To further enhance value and unlock the full potential of the myvac platform, Transgene continues to invest in the optimization of the manufacturing of its INTV candidates, with the aim of reducing turnaround time, enabling scalability and increasing capacity.

Operating revenue and financial visibility

During the first quarter of 2026, operating revenue amounted to €1.4 million compared to €2.5 million for the same period in 2025. It mostly comprised the research tax credit of €1.1 million compared to €2.3 million for the same period in 2025. In Q1 2025, eligible activities against which research tax credit could be claimed comprised manufacturing for the patients in the Phase 2 part of the TG4050 trial in HNSCC; most of these manufacturing activities were completed in Q1 2026, explaining the decrease of the RTC.

As of March 31, 2026, Transgene had €103.8 million in cash, cash equivalents and other financial assets, compared to €111.9 million as of December 31, 2025. Over the first quarter of 2026, Transgene’s net cash burn2 was €8.1 million compared to €14.8 million for the same period in 2025.

Under current plans, the company has sufficient cash to ensure financial visibility until early 2028.

(Press release, Transgene, APR 29, 2026, View Source [SID1234664900])